Genomics Inform Search

CLOSE


Best Practice

  • HOME
  • ABOUT
  • Best Practice
  • Posted in January 9, 2019

Table of Contents

1. Website

The URL address of official web site is https://genominfo.org/.

1) ‘Aims & Scope’ statement

Genomics & Informatics (Genomics Inform) is the official journal of the Korea Genome Organization. It launched in 2003. It aimed at making a substantial contribution to the understanding of any area of genomics or informatics. Its scope includes novel data on the topics of gene discovery, comparative genome analyses, molecular and human evolution, informatics, genome structure and function, technological innovations and applications, statistical and mathematical methods, cutting-edge genetic and physical mapping, next generation sequencing and de novo assembly, and other topics that present data where sequence information is used to address biological concerns.

Especially, Clinical Genomics section is for a short report of all kinds of genome analysis data from clinical field such as cancer, diverse complex diseases and genetic diseases. Genomics & Informatics would encourage submitting the cancer panel analysis data for a single cancer patient or a group of patients. It also would encourage depositing the genome data into designated database. Also, Genome Archives section is for a short manuscript announcing the genetic information of recently sequenced prokaryotic and eukaryotic genomes. These genome archives data can make the rationale for sequencing a specific organism. All submitted manuscripts will be reviewed and selected for publication after editorial review process.

2) Readership

It is primarily for researchers who work for genomics and informatics. Its readership can be expanded to other positions: Professors and science teachers who teach genomics and informatics can access and adopt a variety of data for education; Students can understand the recent trends of the genomics and informatics; Policy makers are able to reflect the results of the articles to the nation-wide science promotion policies especially on the genomics.

3) Authorship criteria

Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright agreement must also be completed by every author.

- Corresponding author and first author: It does allow multiple corresponding authors for one article. Out of them, only one author should correspond with the editorial office. It also does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors.
- Correction of authorship after publication: It does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of the authors involved in the manuscript.

4) Duplicate submission and redundant publication

Submitted manuscripts must not have been previously published or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by Crosscheck upon arrival. If plagiarism or duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed. There will also be penalties for the authors. A letter of permission is required for any and all materials that have been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, figures, and tables.

5) pISSN: N/A because it is online-only journal eISSN; 2234-0742

2. Name of journal

The official journal title is Genomics & Informatics. Abbreviated title is Genomics Inform.

3. Peer review process

Genomics & Informatics reviews all manuscripts received. A manuscript is first reviewed for its format and adherence to the aims and scope of the journal. If the manuscript meets these two criteria, it is dispatched to at least two investigators in the field with relevant knowledge. Assuming the manuscript is sent to reviewers, it waits to receive opinions from at least two reviewers. In addition, if deemed necessary, a review of statistics may be requested. The authors’ names and affiliations are removed during peer review. The acceptance criteria for all papers are based on the quality and originality of the research and its scientific significance. Acceptance of the manuscript is decided based on the critiques and recommended decision of the reviewers. An initial decision will normally be made within 3 weeks of receipt of a manuscript, and the reviewers’ comments are sent to the corresponding author by e-mail. The corresponding author must indicate the alterations that have been made in response to the reviewers’ comments item by item. Failure to resubmit the revised manuscript within 4 weeks of the editorial decision is regarded as a withdrawal. If prolongation of revision period is required, contact the editorial office. A final decision on acceptance/rejection for publication is forwarded to the corresponding author from the editor. All manuscripts from editors, employees, or members of the editorial board are processed the same to other unsolicited manuscripts. During the review process, submitters will not engage in the decision process. Editors will not handle their own manuscripts even if they are commissioned ones. We neither guarantee the acceptance without review nor a very short peer review time for unsolicited manuscripts. Commissioned manuscripts also reviewed before publication. We adopt single -blind peer review in which case, not only authors but also reviewers do not know each other.

4. Ownership and management

1) Information about the ownership

This journal is owned by the publisher, Korea Genome Organization.

2) Management team of a journal

Journal management team (2019~2020)

• Journal Manager: Park, Taesung, Editor, Department of Statistics, Seoul National University, Korea
• Manager of the Review Process: Jung, Dahye, Staff, Korea Genome Organization, Korea
• Ethics Editor: Chung, Yeun-Jun, Department of Microbiology, The Catholic University, Korea
• Statistics Editor: Han, Buhm, Department of Biomedical Sciences, Seoul National University, Korea
• Manuscript Editor: Chang, Soo Hee, Infolumi, Korea
• Layout Editor: Jeong, Eun Mi M2community, Korea
• Website and JATS XML File Producer: Bae, Hyo-Jeong, M2community, Korea

5. Governing body

The governing body is the journal's editorial board.

6. Editorial team and contact information

http://genominfo.org/about/editorial.php

Contact information

http://genominfo.org/about/contact.php

Editorial Office

  • Rm.1011, The Korea Science & Technology Center, 22, Teheran-ro, 7-gil, Gangnam-gu, Seoul, 06130, Korea
  • Tel: +82-2-558-9394
  • Fax: +82-2-558-9434
  • E-mail: kogo3@kogo.or.kr

7. Copyright and licensing

1) Copyright policy

All published papers become the permanent property of the Korea Genome Organization. Copyrights of all published materials are owned by the Korea Genome Organization. Permission must be obtained from the Korea Genome Organization for any commercial use of materials. Every author should sign the copyright transfer agreement forms.

2) Licensing information

This is an open-access journal distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose (http://creativecommons.org/licenses/by/4.0/).

3) Deposit policy

According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk), authors cannot archive pre-print (i.e. pre-refereeing), but they can archive post-print (i.e. final draft post-refereeing). Authors can archive publisher's version/PDF.

8. Author fees

Neither page charge, article processing fee nor submission fee will be applied since 2019. It is the platinum open access journal.

9. Process for the identification of and dealing with allegations of research misconduct

When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.

10. Publication ethics

1) Journal policies on authorship and contributorship

Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author.

- Corresponding author and first author: It does allow multiple corresponding authors for one article. Only one author should correspond with the editorial office. It does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors.

- Correction of authorship after publication: It does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of the authors involved with the manuscript.

2) How the journal will handle complaints and appeals

The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals.

Who complains or makes an appeal?

Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to editor For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.

Who is responsible to resolve and handle complaints and appeals?

The Editor, Editorial Board, or Editorial Office is responsible for them.

What may be the consequence of remedy?

It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee of Publication Ethics(COPE).

3) Journal policies on conflicts of interest / competing interests

The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.

4) Journal policies on data sharing and reproducibility

Open data policy

Data sharing is recommended. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, authors should contact the editorial office.

Clinical data sharing policy

This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at www.icmje.org/recommendations/browse/publishingand-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript and updated in the registry record. Data sharing statements must indicate the following: whether individual deidentified participant data (including data dictionaries) will be shared; what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); and when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism). Illustrative examples of data sharing statements that would meet these requirements are in Table 1.

Table 1. Examples of data sharing statements that fulfill ICMJE requirementsa
Element Example 1 Example 2 Example 3 Example 4
Will individual participant data be available (including data dictionaries)? Yes Yes Yes No
What data in particular will be shared? All of the individual participant data collected during the trial, after deidentification. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Not available
What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
When will data be available (start and end dates)? Immediately following publication. No end date. Beginning 3 months and ending 5 years following article publication. Beginning 9 months and ending 36 months following article publication. Not applicable
With whom? Anyone who wishes to access the data. Researchers who provide a methodologically sound proposal. Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. Not applicable
For what types of analyses? Any purpose To achieve aims in the approved proposal. For individual participant data meta-analysis. Not applicable
By what mechanism will data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement.

Data are available for 5 years at a third-party website (link to be included).
Proposals may be submitted up to 36 months following article publication. After 36 months, the data will be available in our University's data warehouse but without investigator support other than deposited metadata.
Information regarding submitting proposals and accessing data may be found at (link to be provided).
Not applicable

ICMJE, International Committee of Medical Journal Editors.
aThese examples are meant to illustrate a range of, but not all, data sharing options.

5) Journal's policy on ethical oversight

When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

6) Journal's policy on intellectual property

All published papers become the permanent property of the Korea Genome Organization. Copyrights of all published materials are owned by the Korea Genome Organization.

7) Journal's options for post-publication discussions and corrections

The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.

11. Publishing schedule

It is to be published quarterly. Supplement issues may be published.

12. Access

This is an open access journal distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13. Archiving

It is accessible without barrier from Korea Citation Index (https://kci.go.kr), National Library of Korea (http://nl.go.kr), or PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/1928/) in the event a journal is no longer published.

14. Revenue sources

Revenue sources of journal were from the support of publisher (Korean Genome Organization), Korea Government’s support, and advertising rates.

15. Advertising

It accepts advertisements on the following basis:

Eligibility of the advertised products or services

All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.

• Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.

• We reserve the right to decline or cancel any advertisement at any time.

• Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.

Orders

Any individuals or organizations who are interested in advertising their products or services on its website are encouraged to contact the editorial office. The acceptance of advertisement will be discussed by the editorial board and will be ultimately approved by the publisher.

16. Direct marketing

Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the Korea Genome Organization members and presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.



ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
Rm.1011, The Korea Science & Technology Center, 22, Teheran-ro, 7-gil, Gangnam-gu, Seoul, 06130, Korea
Tel: +82-2-558-9394    Fax: +82-2-558-9434    E-mail: kogo3@kogo.or.kr                

Copyright © 2019 by Korea Genome Organization. All rights reserved.

Developed in M2community

Close layer
prev next